Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

L-Arginine and Reduced Tricuspid Regurgitation

Doses used in studies

g/kg/day: 0.1–0.2 (median 0.15, IQR 0.1–0.2) — 1 study
mg/kg/day: 300 (median 300, IQR 300–300) — 1 study

Time to effect

Median: 3 months · IQR 3 months–3 months · Range 3 months–3 months — Reported in 1 of 2 studies

Safety in these studies

Overall tolerabilityNo significant difference
No significant differences in side effects were observed between the two groups, indicating that L-arginine is safe for these patients.
from: Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with
side effectsNo significant difference
No significant differences in side effects were observed between the two groups, indicating that L-arginine is safe for these patients.
from: Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with

2 of 2 papers

The efficacy of oral L-arginine therapy for the treatment of vaso-occlusive pain episodes in children with sickle cell disease.
- 2025-08-27
- RCT · n = 20
- Pediatric hematology and oncology 42(6-7)
- - Aya Mohamed Abd Elglil
  - Mohamed Ramadan El-Shanshory
  - Hamed Mohamed Elsharkawy
  - Walaa Arafa Keshk
  - Nahed M Hablas
  - Lamia M Morad
- PubMed: 40862485
- DOI: 10.1080/08880018.2025.2549365
6 Insights on
- Reduced Tricuspid Regurgitation
- High evidence
- Clinical
TRJV (p-value < 0.001)
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
100 mg/kg/dose three times/day for 15 doses or until discharge
Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children with Sickle Cell Disease and Increased Tricuspid Regurgitant Jet Velocity: a Randomized Controlled Trial.
- 2025-06-17
- RCT · n = 50
- Paediatric drugs 27(5)
- - Dalia A Gomaa
  - Sahar M El-Haggar
  - Mohamed R El-Shanshory
  - Osama El-Razaky
  - Dalia R El-Afify
- PubMed: 40526198
- DOI: 10.1007/s40272-025-00701-w
7 Insights on
- Reduced Tricuspid Regurgitation
- High evidence
- Clinical
After 3 months of treatment, the L-arginine-treated group had significantly lower TRJV levels than the control group
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
0.1-0.2 g/kg/day